Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab withdrawal durability and safety in prurigo nodularis responders
2021-003928-32Phase 3Completed
- Sponsor
- Galderma
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Nemolizumab arm with Placebo arm (2 arms). Primary endpoint: Time to relapse. Started Oct 2021; status: completed.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2021-003928-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003928-32.